7-(2-氯-5-甲氧基苯基)-5-甲基-1,2,4-苯并三嗪-3-胺 | 867330-72-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 7-(2-氯-5-甲氧基苯基)-5-甲基-1,2,4-苯并三嗪-3-胺
• 中文别名: 7-（2-氯-5-甲氧基苯基）-5-甲基-1,2,4-苯并三嗪-3-胺
• 英文名称: 7-(2-chloro-5-methoxyphenyl)-5-methyl-1,2,4-benzotriazine-3-ylamine
• 英文别名: 7-(2-chloro-5-methoxy-phenyl)-5-methyl-benzo[1,2,4]triazin-3-ylamine；7-(2-Chloro-5-methoxyphenyl)-5-methylbenzo[e][1,2,4]triazin-3-amine；7-(2-chloro-5-methoxyphenyl)-5-methyl-1,2,4-benzotriazin-3-amine
• CAS: 867330-72-1
• 化学式: C₁₅H₁₃ClN₄O
• 分子量: 300.747
• InChiKey: JFPQJONXEVRXFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-(2-氯-5-甲氧基苯基)-5-甲基-1,2,4-苯并三嗪-3-胺 在 三溴化硼 、 水 、 碳酸氢钠 作用下， 以 二氯甲烷 为溶剂， 反应 3.5h， 以73%的产率得到3-(3-氨基-5-甲基-1,2,4-苯并三嗪-7-基)-4-氯苯酚
  参考文献：
  名称：

  Benzotriazine inhibitors of kinases

  摘要：

  该发明提供了具有化学式（I）的苯并三唑化合物。该发明的苯并三唑化合物能够抑制激酶，如Src激酶家族成员，以及其他特定的受体和非受体激酶。

  公开号：

  US20050245524A1
• 作为产物：
  描述：

  4-溴-2-甲基-6-硝基苯胺 在 镍 盐酸 、 sodium hydroxide 、 四(三苯基膦)钯 、 氢气 、 potassium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 9.0h， 生成 7-(2-氯-5-甲氧基苯基)-5-甲基-1,2,4-苯并三嗪-3-胺
  参考文献：
  名称：

  Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine—a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays

  摘要：

  We describe the identification of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-l-ylethoxy)phenyl]amine (3), a potent, orally active Src inhibitor with desirable PK properties, demonstrated activity in human tumor cell lines and in animal models of tumor growth. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.11.006

文献信息

• Benzotriazine Inhibitors of Kinases
  申请人：Gong Xianchang

  公开号：US20090275569A1

  公开（公告）日：2009-11-05

  The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.

  该发明提供了具有公式（I）的苯并三氮唑化合物。该发明的苯并三氮唑化合物能够抑制激酶，例如Src激酶家族的成员以及其他特定的受体和非受体激酶。
• BENZOTRIAZINE INHIBITORS OF KINASES
  申请人：Gong Xianchang

  公开号：US20110294796A1

  公开（公告）日：2011-12-01

  The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.

  本发明提供具有公式（I）的苯并三氮唑化合物。本发明的苯并三氮唑化合物能够抑制激酶，如Src激酶家族成员以及其他特定的受体和非受体激酶。
• Development of Prodrug 4-Chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl Benzoate (TG100801): A Topically Administered Therapeutic Candidate in Clinical Trials for the Treatment of Age-Related Macular Degeneration
  作者：Moorthy S. S. Palanki、Hideo Akiyama、Peter Campochiaro、Jianguo Cao、Chun P. Chow、Luis Dellamary、John Doukas、Richard Fine、Colleen Gritzen、John D. Hood、Steven Hu、Shu Kachi、Xinshan Kang、Boris Klebansky、Ahmed Kousba、Dan Lohse、Chi Ching Mak、Michael Martin、Andrew McPherson、Ved P. Pathak、Joel Renick、Richard Soll、Naoyasu Umeda、Shiyin Yee、Katsutoshi Yokoi、Binqi Zeng、Hong Zhu、Glenn Noronha

  DOI：10.1021/jm7011276

  日期：2008.3.1

  Age-related macular degeneration (AMD) is one of the leading causes of loss of vision in the industrialized world. Attenuating the VEGF signal in the eye to treat AMD has been validated clinically. A large body of evidence suggests that inhibitors targeting the VEGFr pathway may be effective for the treatment of AMD. Recent studies using Src/YES knockout mice suggest that along with VEGF, Src and YES play a crucial role in vascular leak and might be useful in treating edema associated with AMD. Therefore, we have developed several potent benzotriazine inhibitors designed to target VEGFr2, Src, and YES. One of the most potent compounds is 4-chloro-3-5-methyl-3-[4-(2-pytrolidin-1-yl-ethoxy)phenylamino]benzo[1,2,4]triazin-7-yl}phenol (5), a dual inhibitor of both VEGFr2 and the Src family (Src and YES) kinases. Several ester analogues of 5 were prepared as prodrugs to improve the concentration of 5 at the back of the eye after topical administration. The thermal stability of these esters was studied, and it was found that benzoyl and substituted benzoyl esters of 5 showed good thermal stability. The hydrolysis rates of these prodrugs were studied to analyze their ability to undergo conversion to 5 in vivo so that appropriate concentrations of 5 are available in the back-of-the-eye tissues. From these studies, we identified 4-chloro-3-(5-methyl-3-[4(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotfazin-7-yl)phenyl benzoate (12), a topically administered prodrug delivered as an eye drop that is readily converted to the active compound 5 in the eye. This topically delivered compound exhibited excellent ocular pharmacokinetics and poor systemic circulation and showed good efficacy in the laser induced choroidal neovascularization model. On the basis of its superior profile, compound 12 was advanced. It is currently in a clinical trial as a first in class, VEGFr2 targeting, topically applied compound for the treatment of AMD.
• J. Med. Chem. 2008, 51, 1546-1559
  作者：

  DOI：——

  日期：——
• EP1809614B1
  申请人：——

  公开号：EP1809614B1

  公开（公告）日：2014-05-07